Akebia Therapeutics (AKBA) Non-Current Deferred Tax Liability (2018 - 2020)
Akebia Therapeutics (AKBA) posted quarterly Non-Current Deferred Tax Liability of $35.1 million for Q1 2020, up 806.04% year-over-year from $3.9 million in Q2 2019, and down 67.9% quarter-over-quarter from $109.4 million in Q4 2019.
Akebia Therapeutics (AKBA) Non-Current Deferred Tax Liability (2018 - 2020) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $35.1 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Non-Current Deferred Tax Liability rose 806.04% year-over-year to $35.1 million; the TTM figure through Mar 2020 stood at $35.1 million (up 806.04% YoY), while the FY2019 annual figure was $109.4 million, down 8.42% from the prior year.
- Non-Current Deferred Tax Liability declined to $35.1 million in Q1 2020 per AKBA's latest filing, from $109.4 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $119.4 million in Q4 2018 and bottomed at $1.8 million in Q3 2019.
- Historically, Non-Current Deferred Tax Liability has averaged $45.4 million across 3 years, with a median of $19.5 million in 2019.
- Annual changes were most pronounced in 2019 — Non-Current Deferred Tax Liability retreated 8.42% — and 2020, when it jumped 806.04%.
- Akebia Therapeutics' Non-Current Deferred Tax Liability stood at $119.4 million in 2018, then dropped by 8.42% to $109.4 million in 2019, then tumbled by 67.9% to $35.1 million in 2020.
- Business Quant data shows AKBA's Non-Current Deferred Tax Liability at $35.1 million in Q1 2020, $109.4 million in Q4 2019, and $1.8 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 35.10 Mn |
| Mar 31, 2020 | 35.10 Mn |
| Dec 31, 2019 | 109.35 Mn |
| Dec 31, 2019 | 109.35 Mn |
| Sep 30, 2019 | 1.75 Mn |
| Sep 30, 2019 | 1.75 Mn |
| Jun 30, 2019 | 3.03 Mn |
| Jun 30, 2019 | 3.03 Mn |
| Mar 31, 2019 | 3.87 Mn |
| Mar 31, 2019 | 3.87 Mn |
| Dec 31, 2018 | 119.41 Mn |
| Dec 31, 2018 | 119.41 Mn |